Anzeige
Mehr »
Login
Freitag, 03.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Schnelle Produktionsaufnahme: Multi-Tenbagger-Potenzial direkt in Spanien?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
50 Leser
Artikel bewerten:
(0)

Pfizer Animal Health and NTRA Charities Team Up to Benefit the Barbaro Memorial Fund

NEW YORK, Jan. 31 /PRNewswire/ -- Pfizer Animal Health and the National Thoroughbred Racing Association (NTRA) have joined forces to help fund laminitis research through the NTRA Charities - Barbaro Memorial Fund. The partnership's aim is to increase awareness of the Fund across the horse industry and encourage further support of cutting edge research into laminitis prevention and treatment.

Owners, trainers and horse enthusiasts alike can contribute directly to the work of the Barbaro Memorial Fund online at RidingwithBarbaro.org. Information on the donation site, and the Fund's goal, will be featured in 2008 Pfizer Animal Health advertising for several equine products, as well as on displays in select retail outlets across the country and at major equine events. Riding with Barbaro awareness bracelets will be available as part of select display promotions.

"Laminitis is a potentially devastating disease that affects horses at all levels of equine sports and across disciplines -- from great Thoroughbred champions like Barbaro, right on to recreational horses loved by their riders and owners," said Kristin Ruff, marketing manager, U.S. equine business, at Pfizer Animal Health. "We wanted to help raise awareness of the Fund's mission and encourage all kinds of horse people to donate what they can toward finding a cure."

"Pfizer's generous contribution and commitment to promote the NTRA Charities - Barbaro Memorial Fund will help further his legacy, both as a courageous and gifted racehorse and as the inspiration for promising new research on equine health," said Alex Waldrop, president and CEO of the NTRA.

The entire horse industry, and horse enthusiasts around the world, watched Barbaro's story unfold after his tragic injury during the 2006 Preakness Stakes. Despite the heroic efforts of a team of leading veterinarians at the University of Pennsylvania's New Bolton Center, it was laminitis that finally ended Barbaro's life in January 2007. While Barbaro will always be remembered for his courage -- both on the track and while facing injury -- his owners wanted his legacy to benefit all horses.

"Gretchen and I hope Barbaro's memory can be carried on through advances in medical research, including a cure for laminitis," said Barbaro's owner, Roy Jackson.

More information on Barbaro's legacy, as well as how to get involved with the Barbaro Memorial Fund and make a donation, can be found online at RidingwithBarbaro.org.

Formed in 1999 as a subsidiary of the National Thoroughbred Racing Association (NTRA), NTRA Charities is a nonprofit, 501 (c) (3) public charity. NTRA Charities works to improve the communities that are home to Thoroughbred racing and to ensure the health and safety of the sport's human and equine athletes.

Pfizer, Inc. , the world's largest research-based biomedical and pharmaceutical company, also is a world leader in discovering and developing innovative animal vaccines and prescription medicines. Pfizer Animal Health is dedicated to improving the safety, quality and productivity of the world's food supply by enhancing the health of livestock and poultry; and in helping horses and pets to live longer and healthier lives. For additional information on Pfizer's portfolio of equine products, visit http://www.pfizerah.com/.

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2008 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.